Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-376-156"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-376-156"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-376-1712
lpv:speaker	lp:Jean-Luc Bennahmias2
lpv:spokenAs	unknown; Mouvement Démocrate (2009-07-14--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 substitute; REGI (2012-01-19--2012-11-04)3 substitute; Delegation for relations with Australia and New Zealand (2012-02-13--2014-06-30)3 member; EMPL (2012-01-19--2014-06-30)3 member; ALDE (2009-07-14--2014-06-30)3
lpv:translated text	"Whilst the Mediator case has brought to light severe shortcomings in the area of the safety of medicines, I welcome the agreement that we have ratified today at first reading. This pharmacovigilance package meets an additional safety requirement. This requires an amendment to the 2001 directive in order to reinforce the legal framework: to create an automatic urgent procedure, to increase transparency obligations for companies, and to provide a list of ‘black symbol’ drugs subject to additional monitoring. These are the new features of this reform which, we hope, will be able to make up for the shortcomings and boost the reliability of the European medicine system."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph